Alexandria Real Estate Equities, Inc. (ARE)
Alexandria Real Estate Equities (ARE) Q4 FFO Match Estimates
Alexandria Real Estate Equities (ARE) came out with quarterly funds from operations (FFO) of $2.39 per share, in line with the Zacks Consensus Estimate. This compares to FFO of $2.28 per share a year ago.
Alexandria to Post Q4 Earnings: What's in the Cards for the Stock?
While ARE's Q4 earnings are likely to have gained from healthy demand for its high-quality life science and lab office properties, high interest expenses are a concern.
Ahead of Alexandria Real Estate Equities (ARE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Alexandria Real Estate Equities (ARE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Very Bad News For Dividend Stocks
Dividend stocks boomed from early July 2024 to late November 2024. However, since then, they have pulled back sharply. I discuss the bad news that may continue weighing on many dividend stocks.
Alexandria Real Estate: The Bottom May Be In, Upgrade To Strong Buy
Alexandria Real Estate Equities offers a 5.3% yield, making it an attractive long-term investment despite recent share price declines and a challenging market. ARE's financials remain strong with solid AFFO and revenue growth, and management has confidence in the stock's undervaluation and future upside. The REIT's balance sheet is robust, with low net debt to EBITDA and significant liquidity, positioning it well against peers like Healthpeak Properties and Omega Healthcare Investors.
Alexandria Real Estate: You Just Got Litt Up!
Alexandria Real Estate's bull thesis was flawed. FFO estimates for ARE have dropped 20% over the last 18 months. The key bear fodder came from the REIT's 2025 guidance.
2 Of My Biggest Losers In 2024 (Both Are Strong Buys)
Falling interest rates and Trump's policies could boost demand, making REITs with strong balance sheets and attractive valuations poised for significant returns. Alexandria Real Estate, a life science REIT, offers stable cash flows, high occupancy, and a strong balance sheet, despite recent underperformance. Rexford Industrial, focused on Southern California, boasts diversified tenants and impressive growth, though faces risks from geographic concentration and potential tariff impacts.
PMG CEO Kevin Maloney on the state of commercial real estate
Kevin Maloney, founder and CEO at PMG, joins CNBC's ‘The Exchange' to discuss his 2025 commercial real estate outlooks, top real estate trends to watch, and more.
3 REITs To Sell Before 2025
REITs have strongly recovered. As a result, some have become overvalued. I highlight 3 REITs to sell before 2025.
REITs Are Suffering, Time To Switch Emotions Off And Act Rationally
Going into 2024, the consensus was that REITs would surge higher. While the base rates have dropped, the REIT investment case has failed. Yet, as long as the objective is to extract durable income, I would argue that now is the right time to make huge moves in the REIT segment.
Alexandria Real Estate Is In Trouble And I'm Ready To Buy
ARE is a leading REIT in life science properties, facing challenges due to a downturn in the life science market. ARE's shares have dropped 55% from their peak but continue to grow FFO per share. ARE's strategic moves include a $500 million share repurchase plan.
Alexandria Real Estate: Excellent Countertrend Play On Multi-Year Big Tech Bust
Alexandria RE is significantly undervalued compared to other U.S. equities, presenting a buy opportunity for contrarian investors. Historical performance during the Dotcom technology bust period suggests ARE could see robust gains years into the future, from countertrend capital flows toward value and income ideas. ARE's balance sheet is strong with low fixed-rate debt and operations stable with mostly pharmaceutical tenants, making it a safer investment amid potential market volatility.
